Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles
In this interview, Thomas Powles, MD, MBBS, MRCP,…
Oncology Data Advisor · i3 Health
October 20, 202311m 39s
Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.